इनसाइडर लेन-देन

EDGAR

Evoke Pharma Inc

निदेशकों, अधिकारियों और 10% से अधिक स्वामियों द्वारा SEC फ़ॉर्म 3, 4 और 5 में रिपोर्ट किए गए लेन-देन, हर फ़ाइलिंग के XML से पढ़े गए। कोड और उनके शब्द SEC के अपने हैं।

फ़ॉर्म 4 लेन-देन के दो कार्य-दिवसों के भीतर दाखिल करना होता है, इसलिए सबसे हाल के लेन-देन अभी दाखिल न हुए हों।

अवधि: 16 नव॰ 2025 या उसके बाद की तारीख के लेन-देन।

ओपन-मार्केट खरीद (कोड P)
0 लेन-देन, — शेयर
ओपन-मार्केट बिक्री (कोड S)
0 लेन-देन, — शेयर

योग सूचीबद्ध दाखिल लेन-देन को जोड़ते हैं; ये रिपोर्ट किए गए की गिनती हैं, किसी दिशा का माप नहीं।

37 में से 1–37 दिखा रहे हैं

इनसाइडर लेन-देन, नवीनतम पहले, जैसा SEC फ़ॉर्म 3, 4 और 5 में दाखिल किया गया
तारीखरिपोर्टिंग स्वामीकोडअर्जित या निपटायाशेयरप्रति शेयर मूल्य, जैसा दाखिल किया गयामूल्य (व्युत्पन्न)बाद में धारित शेयरप्रत्यक्ष या अप्रत्यक्षनियम 10b5-1 चेकबॉक्सटिप्पणियाँस्रोत
17 दिस॰ 2025 19 दिस॰ 2025 को दाखिलNantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
निपटाया (D)1,48,15311.00
16,29,683

व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 1629683.00।

0अप्रत्यक्ष (I) See Footnoteनहीं
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 19 दिस॰ 2025 को दाखिलNantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

व्युत्पन्न प्रतिभूति: Prefunded Warrants — अंतर्निहित Common Stock (4,33,962) — प्रयोग मूल्य 0.0001
निपटाया (D)4,33,96210.999
47,73,148.038

व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 4773148.038।

0अप्रत्यक्ष (I) See Footnoteनहीं
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 19 दिस॰ 2025 को दाखिलNantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

व्युत्पन्न प्रतिभूति: Series A Common Stock Purchase Warrants — अंतर्निहित Common Stock (1,17,019) — प्रयोग मूल्य 8.16
निपटाया (D)1,17,0194.71
5,51,159.49

व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 551159.49।

0अप्रत्यक्ष (I) See Footnoteनहीं
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 19 दिस॰ 2025 को दाखिलNantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

व्युत्पन्न प्रतिभूति: Series C Common Stock Purchase Warrants — अंतर्निहित Common Stock (1,17,019) — प्रयोग मूल्य 8.16
निपटाया (D)1,17,0194.71
5,51,159.49

व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 551159.49।

0अप्रत्यक्ष (I) See Footnoteनहीं
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 19 दिस॰ 2025 को दाखिलNantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

व्युत्पन्न प्रतिभूति: Amended Series A Common Stock Purchase Warrants — अंतर्निहित Common Stock (1,58,531) — प्रयोग मूल्य 0.01
निपटाया (D)1,58,53110.99
17,42,255.69

व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 1742255.69।

0अप्रत्यक्ष (I) See Footnoteनहीं
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 19 दिस॰ 2025 को दाखिलNantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

व्युत्पन्न प्रतिभूति: Amended Series C Common Stock Purchase Warrants — अंतर्निहित Common Stock (2,50,627) — प्रयोग मूल्य 0.01
निपटाया (D)2,50,62710.99
27,54,390.73

व्युत्पन्न: शेयर × प्रति शेयर मूल्य। सटीक मान 2754390.73।

0अप्रत्यक्ष (I) See Footnoteनहीं
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
फ़ाइलिंग खोलें 0001104659-25-123156 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलHill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,218) — प्रयोग मूल्य 5.41
निपटाया (D)1,218——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलHill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45
निपटाया (D)5,833——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलHill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,218) — प्रयोग मूल्य 3.453
निपटाया (D)1,218——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलGARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,479) — प्रयोग मूल्य 5.41
निपटाया (D)1,479——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलGARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (8,750) — प्रयोग मूल्य 4.45
निपटाया (D)8,750——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलGARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,291) — प्रयोग मूल्य 3.453
निपटाया (D)1,291——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलWIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,187) — प्रयोग मूल्य 5.41
निपटाया (D)1,187——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322641 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलWIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45
निपटाया (D)5,833——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322641 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलWIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,187) — प्रयोग मूल्य 3.453
निपटाया (D)1,187——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322641 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलREED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,250) — प्रयोग मूल्य 5.41
निपटाया (D)1,250——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322638 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलREED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45
निपटाया (D)5,833——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322638 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलREED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,250) — प्रयोग मूल्य 3.453
निपटाया (D)1,250——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322638 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलBrady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,218) — प्रयोग मूल्य 5.41
निपटाया (D)1,218——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलBrady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 4.45
निपटाया (D)5,833——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलBrady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,187) — प्रयोग मूल्य 3.453
निपटाया (D)1,187——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलSmeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 5.51
निपटाया (D)5,833——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322645 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलSmeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,125) — प्रयोग मूल्य 3.453
निपटाया (D)1,125——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322645 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलCARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (17,291) — प्रयोग मूल्य 5.27
निपटाया (D)17,291——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322644 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलCARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (11,000) — प्रयोग मूल्य 4.45
निपटाया (D)11,000——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322644 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलD'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (64,840) — प्रयोग मूल्य 5.27
निपटाया (D)64,840——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322637 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलD'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (70,000) — प्रयोग मूल्य 4.45
निपटाया (D)70,000——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322637 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलKowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (17,291) — प्रयोग मूल्य 5.27
निपटाया (D)17,291——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322640 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलKowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (13,000) — प्रयोग मूल्य 4.45
निपटाया (D)13,000——0प्रत्यक्ष (D) नहीं
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322640 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलPYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (5,833) — प्रयोग मूल्य 5.26
निपटाया (D)5,833——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322646 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
17 दिस॰ 2025 17 दिस॰ 2025 को दाखिलPYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

व्युत्पन्न प्रतिभूति: Stock Option (Right to Buy) — अंतर्निहित Common Stock (1,155) — प्रयोग मूल्य 3.453
निपटाया (D)1,155——0प्रत्यक्ष (D) नहीं
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
फ़ाइलिंग खोलें 0001193125-25-322646 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
16 दिस॰ 2025 17 दिस॰ 2025 को दाखिलHill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
निपटाया (D)133——0प्रत्यक्ष (D) नहीं
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
फ़ाइलिंग खोलें 0001193125-25-322642 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
16 दिस॰ 2025 17 दिस॰ 2025 को दाखिलGARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
निपटाया (D)2,330——0अप्रत्यक्ष (I) By Garner Investments, L.L.C.नहीं
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
फ़ाइलिंग खोलें 0001193125-25-322643 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
16 दिस॰ 2025 17 दिस॰ 2025 को दाखिलBrady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
निपटाया (D)27——0प्रत्यक्ष (D) नहीं
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
फ़ाइलिंग खोलें 0001193125-25-322639 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
16 दिस॰ 2025 17 दिस॰ 2025 को दाखिलCARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
निपटाया (D)360——0प्रत्यक्ष (D) नहीं
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
फ़ाइलिंग खोलें 0001193125-25-322644 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
16 दिस॰ 2025 17 दिस॰ 2025 को दाखिलD'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
निपटाया (D)15,509——0प्रत्यक्ष (D) नहीं
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
फ़ाइलिंग खोलें 0001193125-25-322637 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें
16 दिस॰ 2025 17 दिस॰ 2025 को दाखिलKowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
निपटाया (D)11,815——0प्रत्यक्ष (D) नहीं
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
फ़ाइलिंग खोलें 0001193125-25-322640 फ़ाइलिंग के XML से पढ़ा गया इस पंक्ति पर आपत्ति करें

संस्थागत धारक (फ़ॉर्म 13F)

स्टोर में इस जारीकर्ता से जुड़ी कोई फ़ॉर्म 13F स्थिति नहीं है। जो धारक अभी जुड़ा नहीं या जिसने अभी दाखिल नहीं किया, वह अनुपस्थित है, शून्य नहीं।

5% धारक (शेड्यूल 13D और 13G)

SEC के संरचित प्रारूप (2024 के अंत से) में दाखिल शेड्यूल यहाँ पढ़े जाते हैं। पहले के शेड्यूल मुक्त पाठ हैं और पढ़े नहीं जाते।

5% धारक, नवीनतम घटना पहले, जैसा दाखिल किया गया
धारकवर्ग का प्रतिशतधारित शेयरघटना की तारीखफ़ॉर्मस्रोत
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00.0012/17/2025 19 दिस॰ 2025 को दाखिलSCHEDULE 13D/Aसंशोधन 5फ़ाइलिंग खोलें 0001104659-25-123157 इस पंक्ति पर आपत्ति करें
Harkey Wilmot B. Common Stock, par value $0.0001 per share00.0012/17/2025 19 दिस॰ 2025 को दाखिलSCHEDULE 13D/Aसंशोधन 5फ़ाइलिंग खोलें 0001104659-25-123157 इस पंक्ति पर आपत्ति करें
Mack Daniel Common Stock, par value $0.0001 per share00.0012/17/2025 19 दिस॰ 2025 को दाखिलSCHEDULE 13D/Aसंशोधन 5फ़ाइलिंग खोलें 0001104659-25-123157 इस पंक्ति पर आपत्ति करें
Morgan Stanley Common Stock0.03111/30/2025 5 दिस॰ 2025 को दाखिलSCHEDULE 13G/Aसंशोधन 1फ़ाइलिंग खोलें 0000895421-25-000595 इस पंक्ति पर आपत्ति करें
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 5 दिस॰ 2025 को दाखिलSCHEDULE 13G/Aसंशोधन 1फ़ाइलिंग खोलें 0000895421-25-000595 इस पंक्ति पर आपत्ति करें
Klein Roger M. Common Stock, par value $0.0001 per share10.51,63,000.0011/04/2025 12 नव॰ 2025 को दाखिलSCHEDULE 13Dफ़ाइलिंग खोलें 0001651175-25-000007 इस पंक्ति पर आपत्ति करें
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.31,29,000.0011/04/2025 12 नव॰ 2025 को दाखिलSCHEDULE 13Dफ़ाइलिंग खोलें 0001651175-25-000007 इस पंक्ति पर आपत्ति करें
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.992,68,431.0011/03/2025 4 नव॰ 2025 को दाखिलSCHEDULE 13D/Aसंशोधन 4फ़ाइलिंग खोलें 0001104659-25-106048 इस पंक्ति पर आपत्ति करें
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.992,68,431.0011/03/2025 4 नव॰ 2025 को दाखिलSCHEDULE 13D/Aसंशोधन 4फ़ाइलिंग खोलें 0001104659-25-106048 इस पंक्ति पर आपत्ति करें
Mack Daniel Common Stock, par value $0.0001 per share15.992,68,431.0011/03/2025 4 नव॰ 2025 को दाखिलSCHEDULE 13D/Aसंशोधन 4फ़ाइलिंग खोलें 0001104659-25-106048 इस पंक्ति पर आपत्ति करें
Morgan Stanley Common Stock10.51,63,71808/31/2025 8 सित॰ 2025 को दाखिलSCHEDULE 13Gफ़ाइलिंग खोलें 0000895421-25-000528 इस पंक्ति पर आपत्ति करें
Morgan Stanley Smith Barney LLC Common Stock10.51,63,71808/31/2025 8 सित॰ 2025 को दाखिलSCHEDULE 13Gफ़ाइलिंग खोलें 0000895421-25-000528 इस पंक्ति पर आपत्ति करें

प्रतिशत फ़ाइलिंग में नामित वर्ग का है, जैसा धारक ने बताया। समूह के सदस्य प्रत्येक समूह के शेयर रिपोर्ट करते हैं, इसलिए पंक्तियाँ जोड़ी नहीं जातीं।

क्या पढ़ा गया

14 जून 2004 से 13 नव॰ 2026 तक की 20,92,408 फ़ाइलिंग पढ़ी गईं: फ़ॉर्म 3, 3/A, 4, 4/A, 5, 5/A।

जब तक संग्रह पढ़ा जा रहा है, कुछ वर्ष अधूरे हो सकते हैं। यहाँ कम फ़ाइलिंग वाला वर्ष यह नहीं बताता कि कम दाखिल हुईं।

दाखिल वर्ष के अनुसार पढ़ी गई फ़ाइलिंग
दाखिल वर्षपढ़ी गई फ़ाइलिंग
20151
20162,04,322
20172,02,494
20182,02,048
20191,93,638
20201,44,184
20212,24,474
202240,015
20231,99,811
20241,85,386
20252,35,520
20262,54,737

SEC द्वारा XML अनिवार्य करने से पहले की फ़ाइलिंग सूचीबद्ध हैं, निकाली नहीं गईं।

Evoke Pharma Inc पर वापस जाएँ